RT Journal Article
SR Electronic
T1 Genomic epidemiology of the early stages of SARS-CoV-2 outbreak in Russia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20150979
DO 10.1101/2020.07.14.20150979
A1 Andrey B. Komissarov
A1 Ksenia R. Safina
A1 Sofya K. Garushyants
A1 Artem V. Fadeev
A1 Mariia V. Sergeeva
A1 Anna A. Ivanova
A1 Daria M. Danilenko
A1 Dmitry Lioznov
A1 Olga V. Shneider
A1 Nikita Shvyrev
A1 Vadim Spirin
A1 Dmitry Glyzin
A1 Vladimir Shchur
A1 Georgii A Bazykin
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20150979.abstract
AB The ongoing pandemic of SARS-CoV-2 presents novel challenges and opportunities for the use of phylogenetics to understand and control its spread. Here, we analyze the emergence of SARS-CoV-2 in Russia in March and April 2020. Combining phylogeographic analysis with travel history data, we estimate that the sampled viral diversity has originated from 67 closely timed introductions into Russia, mostly in late February to early March. All but one of these introductions came from non-Chinese sources, suggesting that border closure with China has helped delay establishment of SARS-CoV-2 in Russia. These introductions resulted in at least 9 distinct Russian lineages corresponding to domestic transmission. A notable transmission cluster corresponded to a nosocomial outbreak at the Vreden hospital in Saint Petersburg; phylodynamic analysis of this cluster reveals multiple (2-4) introductions each giving rise to a large number of cases, with a high initial effective reproduction number of 3.7 (2.5-5.0).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was presented to the Local Ethics Committee at the Smorodintsev Research Institute of Influenza. The Committee concluded that the study is not covered by the National Standard of the Russian Federation "Good Clinical Practice" (GOST R52379-2005) dated September 25, 2005, because the project does not make use of new biological samples and does not bring forward any new sensitive data. Therefore, according to the rules of the Committee and National Regulations, this project does not require ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGISAID accession IDs of SARS-CoV-2 consensus sequences produced in this study are provided in Supplementary Data 4. The results of minION Nanopore whole-genome sequencing were deposited in SRA (accession numbers pending; will be available by BioProject ID PRJNA645970).